StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a report released on Wednesday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Akari Therapeutics Stock Performance
Shares of NASDAQ AKTX opened at $2.70 on Wednesday. Akari Therapeutics has a one year low of $1.08 and a one year high of $4.40. The company’s fifty day moving average is $3.34 and its two-hundred day moving average is $2.68.
About Akari Therapeutics
Read More
- Five stocks we like better than Akari Therapeutics
- The How And Why of Investing in Oil Stocks
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- The Risks of Owning Bonds
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- Differences Between Momentum Investing and Long Term Investing
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.